Compare Indivior Pharmaceuticals Inc. Common Stock (INDV) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indivior Pharmaceuticals Inc. Common Stock vs New York Times Co — how do they compare? Indivior Pharmaceuticals Inc. Common Stock trades at $34.21 (market cap $4.03B), while New York Times Co trades at $68.5 (market cap $10.83B). The key difference: New York Times Co is far larger — about 2.7× Indivior Pharmaceuticals Inc. Common Stock's market cap, and New York Times Co pays a 1.37% dividend while Indivior Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Indivior Pharmaceuticals Inc. Common Stock for 0 Days and New York Times Co for 82 Days on average.
| INDV | NYT | |
|---|---|---|
Market Cap | $4.03B | $10.83B |
Volume | 2,781,171 | 1,004,378 |
Sector | Health | Media |
52-Week High | $41.83 | $85.86 |
52-Week Low | $24.09 | $54.86 |
Typical Hold Time | 0 Days | 82 Days |
Enterprise Value | $4.32B | $10.22B |
Dividend Yield | — | 1.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
The New York Times Company (NYSE: NYT) trades at $66.88, up 1.21% on the day, with a bearish technical signal but strong fundamental momentum. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.69 surpassing the $0.663 estimate. Revenue growth is robust, climbing from $2.3B in 2022 to $2.8B in 2025, while net income margins expanded to 12.17%. The company declared a quarterly dividend of $0.23 per share, payable in October 2026. Analyst consensus is mixed, with a $81.50 price target but a hold-heavy rating distribution.
Outlook remains cautiously optimistic given solid earnings performance and revenue trajectory, though risks include a shareholder lawsuit alleging reporting bias and ongoing litigation with OpenAI over AI training content. The stock faces near-term technical resistance but benefits from strong cash flow generation and a premium valuation. Investors should weigh fundamental strength against sentiment headwinds and legal overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Indivior Pharmaceuticals Inc. Common Stock
Indivior Pharmaceuticals, Inc. is a pharmaceutical company focused on treatments for opioid use disorder and other addiction-related conditions, including its Suboxone film and tablet products.
Read more on INDV →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
